СЕРЦЕВА НЕДОСТАТНІСТЬ: МІСЦЕ БІОМАРКЕРІВ NT-proBNP ТА sST 2

К.мед.н. Івчина Н. А.

Україна, м. Дніпро, Державний заклад «Дніпропетровська медична академія МОЗ України», кафедра внутрішньої медицини 3

DOI: https://doi.org/10.31435/rsglobal_ws/31082019/6636

 

ПОЛНЫЙ ТЕКСТ PDF

Abstract.

Heart failure is the most common disease in recent decades. Optimizing the diagnosis and prognosis of various types of heart failure is an important task of modern medicine. The use of specific biomarkers to determine the diagnosis of heart failure, prognosis of the disease is an acute problem. To date, known biomarkers are natriuretic peptides and ST2 and its isoforms. These are highly sensitive biomarkers that allow you to personalize the risk of complications in a patient with heart failure. The article discusses both the single, single use of individual biomarkers, as well as the serial identification and combination of biomarkers to evaluate the prognosis.


Keywords: 
chronic heart failure, biomarkers, natriuretic peptide, NT-proBNP, ST2 receptor, prognosis, risk stratification, diagnosis, treatment.

References


1. Ponikowski P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2016; 18(8): 891-975
2. Svennberg E., Lindahl B., Berglund L. et al. NT-proBNP is a powerful predictor for incident atrial fibrillation — validation of a multimarker approach. Int J Cardiol. 2016; 223: 74-81
3. Billebeau G., Vodovar N. et al. Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure. Cohen-Solal A. Eur J Prev Cardiol. 2017; 24(11): 1127-1135.
4. Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Internal Medicine Journal. 2008;38 (2):101–13. DOI:10.1111 / j. 1445–5994.2007.01454. x
5. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A Systematic Review of the Diagnostic Accuracy of Natriuretic Peptides for Heart Failure. Archives of Internal Medicine. 2004;164(18):1978. DOI:10.1001 / archinte. 164.18.1978
6. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. European Journal of Heart Failure. 2005;7(4):537–41. DOI:10.1016 / j. ejheart. 2005.01.022
7. Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL,Baggish AL et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007; 50 (7): 607–613.
8. Chen LQ, de Lemos JA, Das SR, Ayers CR, Rohatgi A. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: The Dallas Heart Study. Clin Chem. 2013; 59: 536–546.
9. Van Kimmenade RR, Pinto YM, Bayes-Genis A, Lainchbury JG, Richards AM, Januzzi JLJr. Usefulness of intermediate aminoterminal pro-brain natriuretic peptide concentration for diagnosis and prognosis of acute heart failure. Am J Cardiol. 2006; 98: 386–390.
10. Richards A.M. The relationship of plasma NT-proBNP to age and outcomes in heart failure. JACC Heart Fail. 2016; 4(9): 746-748.
11. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/ AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017;70:776–803.
12. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of сardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
13. Pascual-Figal DA, Garrido IP, Blanco R, Minguela A, Lax A, Ordonez-Llanos J et al. Soluble ST2 is a
marker for acute cardiac allograft rejection. Ann Sur Thorac.2011; 92 (6): 2118–2124.
14. May Khal A., Ky B. Defining the Role of ST2: A Multimarker Approach?// J Card Fail.2012; 18 (4):311-312
15. Daniels LB, Bayés Genís A. Using ST2 in cardiovascular patients: a review. Future Cardiol 2014;10:525–39.
16. Bayés — Genís A, Januzzi JL, Gaggin HK, et al. ST2 pathogenetic profile in ambulatory heart failure
17. Januzzi JL, Horne BD, Moore SA, Galenko O, Snow GL, Brunisholz KD et al. Interleukin receptor family member ST2 concentrations in patients following heart transplantation. Biomarkers. 2013; 18 (3): 250–256.
18. Baba Y, Maeda K, Yashiro T, Inage E, Kasakura K, Suzuki R et al. GATA2 is a critical transactivator for the human IL1RL1/ST2 promoter in mast cells/basophils: Opposing roles for GATA2 and GATA1 in human IL-1RL1/ST2 gene expression. J Biol Chem. 2012; 287 (39): 32 689–32 696.
19. Ho JE, Chen WY, Chen MH, Larson MG, McCabe EL, Cheng S et al. Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J Clin Invest. 2013; 123 (10): 4208–4218.
20. Moliner P. Bayes-Genis A. et al Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. Int J Cardiol. 2018; 257: 188-192
21. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. Рабочая группа по диагностике и лечению острой и хронической сердечной недостаточности Европейского общества кардиологов (ESC) при участии Ассоциации сердечной недостаточности (АСН) в составе ESC. Российский кардиологический журнал. 2017; 1(141): 7-81.
22. Aimo A, Vergaro G, Ripoli A, et al. Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. J Am Coll Cardiol HF 2017;5:287–96.
23. Aimo A, Vergaro G, Passino C, et al. Prognostic value of soluble suppression of tumorigenicity — 2 in chronic heart failure: a meta- analysis. А Am Coll Cardiol HF 2017;5:280–6
24. Socrates et al. Interleukin family member ST2 fyl mortality in acute dyspnoea. L.Int Med 2010; 268: 493-500
25. Januzzi JL, Horne BD, Moore SA, Galenko O, Snow GL, Brunisholz KD et al. Interleukin receptor family member ST2 concentrations in patients following heart transplantation. Biomarkers. 2013; 18 (3): 250–256.
26. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C,Guo W, Bode Ch et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117 (15): 1936–1944.
27. Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J et al. Serial sampling of ST2 predicts 90-day mortality following destabilized HF. J Card Fail. 2008; 14 (9): 732–738.
28. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, Casas T, Garrido IP, Bonaque JC et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: Complementary role for risk stratification in acutely decompensated heart failure. Eur JHeart Fail. 2011; 13: 718–725.
29. Lupоn J, de Antonio M, Vila J, et al. Development of a novel heart failure risk tool: the Barcelona bio-heart
failure risk calculator (BCN bio-HF calculator). PLoS ONE 2014;9:e85466